#ASCO16 news about #melanoma #skincancer

Online now: CheckMate064-nivolumab then ipilimumab more beneficial, more tox vs reverse order in #melanoma https://t.co/dpiSm9c5uq #ASCO16

— The Lancet Oncology (@TheLancetOncol) June 4, 2016